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ABSTRACT
Although sometimes presenting as an indolent lymphoma, mantle cell lymphoma 
(MCL) is an aggressive disease, hardly curable with standard chemo-immunotherapy. 
Current approaches have greatly improved patients’ outcomes, nevertheless the 
disease is still characterized by high relapse rates. Before approval by EMA, Italian 
patients with relapsed/refractory MCL were granted ibrutinib early access through a 
Named Patient Program (NPP). 
An observational, retrospective, multicenter study was conducted. Seventy-
seven heavily pretreated patients were enrolled. At the end of therapy there were 
14 complete responses and 14 partial responses, leading to an overall response rate 
of 36.4%. At 40 months overall survival was 37.8% and progression free survival was 
30%; disease free survival was 78.6% at 4 years: 11/14 patients are in continuous 
complete response with a median of 36 months of follow up. Hematological toxicities 
were manageable, and main extra-hematological toxicities were diarrhea (9.4%) and 
lung infections (9.0%). Overall, 4 (5.2%) atrial fibrillations and 3 (3.9%) hemorrhagic 
syndromes occurred.
In conclusions, thrombocytopenia, diarrhea and lung infections are the relevant 
adverse events to be clinically focused on; regarding effectiveness, ibrutinib is 
confirmed to be a valid option for refractory/relapsed MCL also in a clinical setting 
mimicking the real world.
INTRODUCTION
Mantle cell lymphoma (MCL) is a rare, clinically 
aggressive B-cell lymphoma that accounts for 6–8% of 
all non-Hodgkin lymphoma cases [1]. It is a disease that 
predominantly affects older men (median age, 65 years), 
usually presents as late-stage disease and is associated 
with a poor prognosis [2]. While high response rates are 
seen with induction chemo-immunotherapy, relapse is 
almost universal, occurring linearly even beyond 6 years 
from the end of therapy [3]. Management of relapsed 
disease is challenging, and treatment decisions are 
based on patient’s and disease characteristics. Following 
progression, subsequent treatment is often ineffective and 
survival is short [4].
Ibrutinib is an oral inhibitor of B-cell receptor 
signaling through targeting the Bruton’s tyrosine kinase 
(BTK) which has become the preferred therapy at relapse 
for a majority of patients. In the landmark phase II 
international trial reported by Wang et al., 111 patients 
with relapsed/refractory MCL (rrMCL) were treated 
with ibrutinib 560 mg daily until disease progression or 
unacceptable toxicity [5]. An ORR of 68% was achieved 
including 21% complete responses (CR). With extended 
follow-up, median progression-free survival (PFS) was 
13 months with median overall survival (OS) of 22.5 
months [6]. The median duration of response (DoR) was 
17.5 months with 31% PFS at 24 months. Patients with 
refractory rather than relapsed disease at study entry 
had inferior outcomes with a median OS of 13 months. 
Ibrutinib was compared with temsirolimus in a phase III 
trial of 280 patients with rrMCL. Ibrutinib was associated 
with a greater ORR (72%, P < 0.0001) and CR rate (19%) 
as well as a significantly longer PFS (14.6 vs. 6.2 months, 
P < 0.0001) [2]. After ibrutinib approval by FDA and 
before official approval by EMA, patients with rrMCL 
with unsatisfied critical medical urgency were granted 
ibrutinib early access through a Named Patient Program 
(NPP) by compassionate use in Italy. Herein, we report 
the Italian multicenter experience with ibrutinib in rrMCL 
as we believe that data collected outside a controlled trial 
give useful additional information about the clinical use, 
effectiveness, and safety profile of the drug when applied 
in a real life context.
RESULTS
Thirty-three Centers were initially involved, 29 
Centers were actually activated. Of the 80 patients 
expected, 77 were actually enrolled (3.7% difference).
Characteristics of the 77 patients are summarized in 
Table 1. Participants had an Eastern Cooperative Oncology 
Group performance status score ≤2, and normal organ 
function including peripheral blood counts within the 
normal range. All patients underwent baseline assessments 
including physical examination, routine hematology and 
biochemistry as well as imaging prior to therapy. Patients 
received ibrutinib at the initial dose of 560 mg daily. First 
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diagnosis of MCL was established between 1995 and 
2014. The median age at ibrutinib was 65.2 years (range, 
34.6–81.3 years); fifty-nine patients were males and 18 
were females. Fourteen (18.2%) had systemic symptoms 
at baseline; an advanced stage (i.e. stage III or IV) was 
present in 69 (89.6%) patients.
The median number of prior lymphoma-related 
systemic regimens was 3 (range, 1–10) including high dose 
chemotherapy and autologous stem cell transplantation 
(ASCT) in 27 (35%) patients. Twenty-one (27.3%) had 
already received bortezomib, 8 (10.4%) temsirolimus, and 
25 (32.5%) lenalidomide. Thirty-seven (48.1%) patients 
had a disease that was refractory to frontline therapy 
(primary refractory patients) and 17 patients (22.1%) had a 
disease that was refractory to last therapy before ibrutinib. 
Response
All the patients received ibrutinib for a median of 6 
cycles (range, 1–20). Among the 77 patients, 14 (18.2%) 
achieved CR and 14 (18.2%) obtained a PR with an ORR 
of 36.4%; among the remaining patients, 8 (10.4%) had 
stable disease (SD) and 41 (53.3%) showed progression 
of disease (PD), respectively. 
Among the 37 primary refractory patients, 3 (8.1%) 
achieved CR and 2 (5.4%) had a PR yielding an ORR 
of 13.5%; in the subset of the 17 patients who were 
refractory to the last line we observed 4 (23.5%) CR and 
3 (17.6%) PR, with an ORR of 50.1%. The difference in 
ORR between these two subsets of patients is statistically 
significant (p < 0.05). No differences in outcome were 
Table 1: Patient demographics and characteristics at baseline
Total population
Patients, N 77
Median age at diagnosis, years (range) 65.2 (34.6–81.3)
Median time from diagnosis-ibrutinib, years (range) 68.6 (38.5–83.7)
Median time from last relapse-ibrutinib, days (range) 37 (10–360)
Males, N (%)
Females, N (%)
59 (76.6)
18 (23.4)
Previous cardiac problems, N (%) 2 (2.6)
Stage at diagnosis, N (%)
- I/II (E*)
- III
- IV
4 (5.2)
12 (15.6)
61 (79.2)
Stage at ibrutinib, N (%)
- I/II 
- III
- IV
8 (10.4)
14 (18.2)
55 (71.4)
Blastoid variant, N (%) 3 (3.9)
ECOG† performance status, N (%)
- 0
- 1
- 2
- 3
37 (48.1)
24 (31.2)
15 (19.5)
1 (1.2)
B symptoms, N (%) 14 (18.2)
Last therapy before ibrutinib, N (%)
RCHOPa
Bendamustine
Lenalidomide
Temsirolimus
Bortezomib
RBACb
transplant
17 (22.1)
19 (24.7)
20 (26.0)
4 (5.2)
6 (7.8)
9 (11.7)
2 (2.6)
- Refractory to most recent therapy, N (%)
- Refractory to first line therapy, N (%)
17 (22.1)
37 (48.1)
Abbreviations: *E: extranodal; †ECOG: Eastern Cooperative Oncology Group; aRCHOP: rituximab, cyclophosphamide, 
doxorubicin, vincristine, and prednisone; bRBAC: rituximab, bendamustine and cytarabine.
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observed between patients refractory to and patients 
relapsed after last therapy before ibrutinib. The number 
of previous therapies does not affect patients’ responses 
and outcomes.
Globally, at a median follow up of 38 months, OS 
was 37.8% at 40 months (Figure 1) with a median of 16 
months. PFS at 40 months was 30% and the median was 
reached at 12.9 months (Figure 2). Disease free survival 
(DFS) was 78.6% at 48 months (Figure 3) since 3 (21.4%) 
out of 14 CR patients relapsed while 11 patients were 
in continuous CR (CCR) at the latest follow up, with a 
median DoR of 36 months; among these patients, three 
received a transplant consolidation (1 with ASCT and 
2 with allogeneic transplant [alloSCT]). The DoR was 
79.2% at 40 months (Figure 4).
Globally, 37 patients underwent further treatments 
after ibrutinib; among them, 32 patients received 
subsequent chemotherapy or chemoimmunotherapy, 
including 5 patients who received lenalidomide, one 
temsirolimus, one bortezomib; 7 were rechangelled with 
ibrutinib. The remaining 5 patients received ibrutinib as 
bridge to transplant. In particular: 1 PR patient remained 
in PR after alloSCT; 1 PR converted to a CR with alloSCT; 
2 patients in CR consolidated their response with alloSCT 
and ASCT respectively; 1 patient in CR rapidly developed 
an acute myeloid leukemia (AML) after alloSCT. Seven 
patients were rechallenged with ibrutinib: 2 achieved a 
CR, while the other 5 acquired resistance to drug.
Safety
Besides PD, reasons for early discontinuations (N = 
19) were: transplant procedure (N = 3), 1 lung cancer, 1 
AML, 1 death due to unknown cause, and adverse event 
(AE) (N = 13). AEs in detail were: 2 diarrhea, 1 atrial 
fibrillation, 2 infections, 1 herpes zoster, 2 hemorrhages, 
5 leukocytosis/lymphocytosis. The patient with atrial 
fibrillation did not interrupt ibrutinib at the onset of 
arrhythmia: he started enoxaparin but the treatment was 
complicated with an hemorrhagic syndrome (grade 2) 
leading to permanent interruption of ibrutinib. Six patients 
interrupted ibrutinib due to hematological toxicities and 
only one restarted at a lower dose.
Fifteen patients developed hematological toxicities 
other than lymphocytosis: thrombocytopenia in 11 cases (2 
grade 4 and 1 grade 3, related to bone marrow infiltration, 
while the other 8 were judged related to ibrutinib); 2 
cases of neutropenia, 1 AML, 1 cytopenia (all grade 4 
and judged unrelated to ibrutinib). Lymphocytosis was 
present in 14 patients at baseline. Ten out of 14 cases of 
lymphocytosis persisted until the end of the treatment. 
On the other hand, 13 (16.9%) subjects developed 
lymphocytosis during therapy, and it then persisted until 
the end of treatment. The 80% of hematological toxicities 
occurred in the first 3 months of therapy.
Main extra-hematological toxicities were diarrhea 
(9.4%) and lung infections (9.0%) which all lead to early 
drug discontinuation. Overall, 4 (5.2%) atrial fibrillations 
and 3 (3.9%) hemorrhagic syndromes occurred. The 88% 
of extra-hematological toxicities occurred in the first 3 
months of therapy.
DISCUSSION
Outcomes are poor for patients with MCL who 
relapse after initial therapy. There are currently five agents 
licensed for the treatment of rrMCL: bortezomib (only 
in USA), temsirolimus (only in Europe), lenalidomide, 
acalabrutinib (since October 2017, only in USA) and 
ibrutinib. Nevertheless, there is no standard of care at 
Figure 1: Overall survival.
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Figure 2: Progression free survival.
Figure 3: Disease free survival.
Figure 4: Duration of response.
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present in this setting and a definitive MCL treatment 
algorithm is yet be established [7]. Ibrutinib seems to be 
one of the more active single agent in refractory/relapsed 
disease also in the real life setting, but direct comparisons 
between the four drugs have been never performed in 
either clinical trials or retrspectice experiences [5, 8].  
In our multicenter retrospective study, we evaluated 
rrMCL patients who were treated with single agent 
ibrutinib in everyday clinical practice; the most part of 
the 77 patients were heavily pretreated and at least 50% 
were primary refractory. Our analysis reported a CR rate 
of 18.2% that was similar to those observed in clinical 
trials investigating similar MCL populations treated with 
ibrutinib as single agent; on the contrary, the ORR rate 
observed was only 36.4%, rather inferior if compared 
with data already published [5, 8]. One cause may be the 
wrong interpretation of lymphocytosis. Approximately 
a third of patients with MCL develops lymphocytosis 
during ibrutinib therapy which typically peaks 4 weeks 
after initiation before slowly declining over subsequent 
cycles. This transient lymphocytosis does not reflect 
resistance or disease progression and can be regarded 
as part of a response to treatment in the context of 
diminishing tissue bulk elsewhere [9]. In the present 
work, 14 patients at baseline presented with lymphocytosis 
and 10 had persistent lymphocytosis until the end of 
treatment. Seventeen percent developed lymphocytosis 
during treatment with ibrutinib and it was present at 
end of treatment too. Physicians wrongly considered 
lymphocytosis as progression of disease and stopped 
the treatment. Isolated lymphocytosis should not lead to 
a diagnosis of disease progression in ibrutinib-treated 
subjects as lymphocytosis is not to be considered an AE 
per se but reflects the pharmacodynamics of the drug [9]. 
Regarding survivals functions, our real life data 
compared with the pooled data from clinical studies, show 
similar median PFS (12.9 vs 12.8 months, respectively) 
while the median OS appears inferior in our series (16.0 
vs 25.0 months) [2, 5, 10, 11]. On the contrary, our median 
DoR was not reached in comparison with 18.6 months of 
the pooled data report. Of note, 11 (14.2%) patients are 
in still CR with a median DoR of 36 months at the latest 
available follow up. 
Failure after ibrutinib is an urgent medical 
need: multiple studies have shown that MCL patients 
demonstrate a poor outcome in this case [12, 13]. In our 
report, patients who failed ibrutinib therapy underwent 
further treatment: 5 out of the 7 patients who underwent 
ibrutinib rechallenge acquired resistance. This is a 
common issue which may presumably be solved at least 
partially with combination or right sequencing therapy 
[13, 14]. Lenalidomide could be an effective opportunity 
even if in our study the patients (only five) who underwent 
lenalidomide after ibrutinib failed to achieve response 
[15, 16]. On the other hand, patients who consolidated 
response with SCT had better outcomes.
It is confirmed that ibrutinib has a favorable safety 
profile, with mild and generally transient side effects. In 
clinical trial and real life experience, atrial fibrillation 
(5–8%) and bleeding (3–5%) have emerged as the most 
challenging safety issues and physicians are inclined to 
suspend the drug in some instances so as not to make 
mistakes in the management of these AEs. As a result, 
patients stop benefiting from a life-saving drug. Recently, 
practical guidelines for the management of ibrutinib in the 
real life have been published, focusing on atrial fibrillation 
and bleeding: this helps physicians to better manage 
these particular situations allowing responder patients to 
continue therapy with ibrutinib [17].
To note that the modest side effect profile of 
ibrutinib candidates this drug to potential combination 
therapies. 
Despite the known potential bias of all observational 
studies, the present report on the real life experience 
provides an important contribution to medical knowledge: 
we have learnt in fact that ibrutinib treatment is effective 
and well tolerated also in everyday clinical practice. 
Long-term outcomes and new structured clinical trials are 
awaited.
PATIENTS AND METHODS
An observational, non-interventional, multicenter, 
retrospective observational study was conducted to 
assess effectiveness of ibrutinib and to analyze outcomes 
and toxicity data of patients managed in a non-trial 
setting. The study was approved by our institutional 
board (Azienda Ospedaliera-Universitaria di Bologna, 
Policlinico S.Orsola-Malpighi, coordinating Center) and 
by all involved Ethical Committees and registered in the 
Italian Registry of Observational Studies. All participants 
gave written informed consent in accordance with the 
Declaration of Helsinki.
A shared database was used after the approval of all 
the authors and variables were strictly defined to avoid 
bias in reporting data. From July 2014 to January 2015, 
a total of 29 Italian centers utilized ibrutinib according 
to the NPP in 77 patients with rrMCL. Centers were 
consecutively involved to avoid selection bias. Data were 
collected by local investigators but were monitored and 
centrally reviewed.
The primary endpoints of the study were the ORR 
and the CR rate; secondary endpoints were the OS, PFS, 
disease-free survival (DFS), DoR, and the incidence, 
severity, and type of any AE occurring during and near 
after treatment. 
Response was assessed by imaging using the 
International Working Group revised response criteria for 
malignant lymphoma [18].
Safety and tolerability were evaluated by classifying 
AEs according to NCI CTCAE version 4.0. OS was 
defined as the time from initiation of therapy to death from 
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any cause and was censored at the date of last available 
follow up. PFS was measured from initiation of therapy 
to progression, relapse, or death from any cause and was 
censored at the date of last available follow up. DFS was 
calculated for CR patients from the first documentation of 
response to the date of relapse or death due to lymphoma 
or acute toxicity of treatment. DoR was calculated from 
the first objective tumor response (CR or PR) to first 
documentation of progression or death [18].
Demographics and patients’ characteristics were 
summarized by descriptive statistics. 
Survival functions were estimated by using 
the Kaplan–Meier method and were compared using 
log-rank test.
Statistical analyses were performed with Stata 11 
(StataCorp LP, TX) and p values were set at 0.05.
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